The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
One of the risks with the uncontrolled trail is that the doctors involved, through a form of unconscious selection bias, put their 'healthiest' patients on the trial (e.g. patients who haven't had so much treatment that their immune system has become significantly weakened). This could lead to the results being skewed as the trial participants are those that would have responded well to the CPI's on their own. This IMO is one of the reasons that in a small uncontrolled trial it is difficult to be sure exactly what difference the drug has made compared to the performance of CPI's on their own. This bias effect would be eliminated in larger controlled trials, which may well be why we see trials where the drug appears to have had a positive impact in phase 1/2 but then fails in phase 3.
Having said this, the results so far have been so good that I'd be very surprised if SCIB1 wasn't having a materially positive impact.
Given that the AACR presentation by LD in April wasn't mentioned in the RNS this leads me to think that we may get a separate RNS for that one with an update on recruitment, patient progress etc. Here's hoping.
Sounds like you are thrashing around Fevertreeman !!!
Interesting really ? A £20k trade. How so ?
Video of the Angle conference presentation which took place today (thanks for flagging the conference to goosed on AD).
hTTps://www.youtube.com/watch?v=ZqaWMUx7GhE
Quite the opposite Matt - based on what Lindy actually said I would expect at least one or two mAb deals this year (5 parties in discussion, vying for exclusivity).
'Oh and of course they initially went down the wrong DDA approval pathway, which set things back quite a bit.
Have to wonder why that was as there are plenty of consultants firms that help companies prepare submissions. '
LOL. It was a consulting firm that sent them down the wrong path.
The benefit of using NGS provided by the mayor players in this space is that there is a very large installed base of those machines across labs globally, so all Angle need to do is to publish the protocol for processing the CTC's through those systems and then those labs can carry out the CTC analysis themselves (assuming they buy a parsortix system) and can therefore provide the future Ovarian / Prostate tests and other tests themselves. If Angle stuck with their in-house genetic analysis solution for their tests then the labs would need to buy the Angle genetic testing tech as well as buying the parsortix systems and this would be a major blocker to other labs offering the tests.
Hi VanVan
we know that Genmab are interested in a further Glymab and that there is work ongoing with another company to determine if Scancell's tech works with theirs, and no doubt there are other discussion underway since the new Business Development Director came on board. The next deal can't be too far away.
AN invested in the fundraise at a significantly higher price that this.